 fluorescent with single strand 2733.jpg "Our New Fluorescent mRNA")
“We are proud and delighted that our innovative proposal was selected and rewarded by Eurostars funding. The synergistic combination of our consortium technologies will definitely provide a breakthrough in this exhilarating field of immunotherapy. We look forward to a fruitful collaboration and successful outcome” said Olivier Zelphati, CEO of OZ Biosciences Sas.
Eurostars, a European joint programme, co-funded from the national budgets of several EUREKA countries and by the European Union through Horizon 2020 has awarded, through a highly-competitive selection process, the Project “A novel modified natural killer (NK) cell immunotherapy for the treatment of solid tumours” – MODIFY-NK.
The consortium composed of Glycostem Therapeutics BV (The Netherlands), YUMAB GmbH (Germany), Explicyte (France) and OZ Biosciences SAS (France) will deliver a novel cell-based therapy to treat solid tumours with chimeric antigen receptors (CAR) expressing allogeneic (i.e. from a patient independent donor) natural killer (NK) cells. These CARs strongly improve solid tumour targeting and killing potential. The efficacy of this clinical grade CAR-NK cell product will be validated in a preclinical solid tumour model and the therapy will be ready for clinical studies within 24 months after completion of this project.